Biblio

Author Title [ Type

] Year

Filters: Author is Micallef, Ivana N [Clear All Filters]

Journal Article

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Markovic SN. Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis. Leuk Res. 2019;81:1-9.

Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023.

Porrata LF, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Paludo J, Durani U, Markovic SN. Day 100 Natural Killer Cell/CD14+HLA-DR ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. Clin Transplant. 2023:e15211.

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Bone Marrow Res. 2013;2013:658371.

Porrata LF, Burgstaler EA, Winters JL, Jacob EK, Gastineau DA, Suman VJ, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, et al. Immunologic Autograft Engineering and Survival in Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2016.

N Bennani N, Kim HJin, Pederson LD, Atherton PJ, Micallef IN, Thanarajasingam G, Nowakowski GS, Witzig T, Feldman AL, Ansell SM. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022;10(6).

Desai SH, Spinner MA, Evens AM, Sýkorová A, Bachanova V, Goyal G, Kahl BS, Dorritie KA, Azzi J, Kenkre VP, et al. Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. Blood Adv. 2023.